{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-056335","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2023-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.947471+00:00","generated_at":"2026-06-09T06:13:02.093617+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Biomea Fusion reports Q3 net loss of $28.4M, advances diabetes and oncology pipeline","bullets":["Net loss of $28.4M for Q3 2023 vs $22.9M in Q3 2022; cash of $199.5M as of Sep 30, 2023.","COVALENT-111 expansion cleared; 84% of patients showed HbA1c reduction at Week 4; enrollment in ~200 type 2 diabetics.","IND cleared for COVALENT-112 (BMF-219) in type 1 diabetes; enrollment of 150 adults expected to start in Q4 2023.","Initial AML data: 2 CRs out of 5 patients with menin-dependent mutations at Dose Level 4; BMF-500 first patient dosed.","Appointed Juan Pablo Frías, M.D., as Chief Medical Officer to oversee diabetes clinical development."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-056335","json":"https://secwatch.observer/filing/0000950170-23-056335.json","markdown":"https://secwatch.observer/filing/0000950170-23-056335.md","text":"https://secwatch.observer/filing/0000950170-23-056335.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000095017023056335/0000950170-23-056335-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000095017023056335/bmea-20231030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T06:13:02.093617+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"35fe284e21160d05b0e24e2bcbcdc924d785b885","claim":"Biomea Fusion, Inc. reported financial results for the quarter ended September 30, 2023.","evidence_excerpt":"On October 30, 2023, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840439/000095017023056335/0000950170-23-056335-index.htm","confidence":0.6,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}